Osteosarcoma is a rare cancer affecting the bones. It is also the most common bone cancer in children and young adults but can also occur in older adults. It mostly affects the knee, thigh bone, shin bone or upper arm. Symptoms include pain and swelling around the affected bone. Current treatment options have improved the prognosis of this disease, however, a recurrence of osteosarcoma may appear in other parts of the body after the primary cancer has been treated. The majority of the recurrences occur in the lungs. Symptoms of lung involvement may include cough, breathlessness, pain or discomfort in the chest.
Inhaled Lipid‐complexed Cisplatin or inhaled liposomal cisplatin (ILC) is an anticancer drug being developed for the treatment of osteosarcoma that has reoccurred and spread to the lungs. Cisplatin is already available in the UK as an intravenous injection for treating multiple types of malignant conditions. ILC is administered via inhalation has the potential advantage to deliver the drug directly to the site of action (the lungs) with significantly reduced systemic side effects and toxicities. If licensed, ILC will offer an additional treatment option with the potential to improve effectiveness and safety for patients with pulmonary relapse of osteosarcoma.
Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation.